Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases

Version 1 : Received: 19 December 2023 / Approved: 20 December 2023 / Online: 20 December 2023 (10:17:06 CET)

How to cite: Sharma, A.; Mehra, V.; Kumar, V.; Prakash, H. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases. Preprints 2023, 2023121509. https://doi.org/10.20944/preprints202312.1509.v1 Sharma, A.; Mehra, V.; Kumar, V.; Prakash, H. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases. Preprints 2023, 2023121509. https://doi.org/10.20944/preprints202312.1509.v1

Abstract

Neurodegenerative diseases like Alzheimer's diseases are irreversible, progressive, and refractory in nature and managed very poorly. AD is manifested with the aggregation of unfolded proteins, synaptic pathology and dementia and poses challenges to the health care system globally. Only very few treatments with minimal effect are available to the patients and their caregivers. Despite numerous clinical trials which were launched for AD, unfortunately, most of them failed in satisfying the pharmacological criteria. At cellular levels, many signaling pathways have been proposed for the sterile / refractory behavior of degenerating neurons. Among those, Mitogen activated protein kinases (MAPKs) are the critical cellular networks which are involved in the development of Alzheimer’s disease. Several studies have demonstrated a favorable impact of MAPK inhibition on inflammatory programming, synaptic plasticity, and memory problems in mouse models of AD. In view of this, various clinical trials were launched with several MAPK inhibitors (with good safety profile and less side-effects) have yielded positive results in AD patients suggesting that MAPK targeting may be effective for reducing the pathogenesis of AD, but due to selectivity, dosing and patient stratification, this aspect still need development. In view of selectivity and off-target effects, only a few MAPK inhibitors have been employed in clinical trials against AD indicating a scope of development in this area. Therefore, this study focuses on MAPK based interventions as an upcoming and innovative approach for alleviating AD with special emphasis on clinical studies.

Keywords

Alzheimers Diseases; MAPK; Neuro-Immunological interaction; Neuronal Fibroblast; Microglia; Th1/17 responses

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.